Optical coherence tomography (OCT) developer Michelson Diagnostics said that a U.K. study concluded its OCT technology can accurately reveal the margins of skin cancers in the eyelids and skin surrounding the eye.
The 15-patient study, which was conducted by the department of ophthalmology at Maidstone and Tunbridge Wells National Health Service (NHS) Trust, found a positive correlation between histology and tumor margins determined using Michelson's VivoSight OCT scanner. In addition, the research team determined that VivoSight enabled identification of basal cell carcinoma features with higher sensitivity and specificity than previous OCT systems, Michelson said.
The results were published online on 15 May in the British Journal of Ophthalmology.
